The Evolving Dynamics of Access and Reimbursement in China
Market access and reimbursement in healthcare is a persistent problem in China despite a rapidly expanding and increasingly affluent middle class... In DRG Blog/ August, 2019 In China 4+7 equals quality generic medicines at affordable costs
China is overhauling its healthcare system to align with the changing economic and demographic situation China’s healthcare system is undergoing a... In DRG Blog/ May, 2019 The FDA approves Alnylam’s Onpattro (patisiran) for ATTR-FAP patients.
Is this the herald of a new era for amyloidosis? On August 10, 2018, the FDA approved Alnylam’s Onpattro (patisiran) for the treatment of ATTR-FAP (... In DRG Blog, Niche and Rare Disease/ August, 2018 The New Kid on the Block – What to Expect from Rigel’s Tavalisse for ITP
The FDA recently approved Rigel Pharmaceuticals’ Tavalisse (fostamatinib) for adult patients with chronic immune thrombocytopenia (ITP) who have had... In DRG Blog, Niche and Rare Disease, Drug Watch/ May, 2018 Gene Therapies for Retinitis Pigmentosa Come in to Focus
On December 19, 2017, the FDA approved Spark Therapeutics’ gene therapy Luxturna for patients with confirmed biallelic RPE65 mutation-associated... In DRG Blog, Niche and Rare Disease, Drug Watch/ February, 2018 Let There Be Light
Expectations for Spark Therapeutics’ Gene Therapy Luxturna in Retinitis Pigmentosa and Leber Congenital Amaurosis The FDA’s January 2018... In DRG Blog, Niche and Rare Disease, Drug Watch/ September, 2017 AB Science’s Masitinib for ALS, will it hit or miss?
Earlier this year, AB Science announced positive top-line results from a Phase II/III trial of their lead candidate, the oral tyrosine... In DRG Blog, Niche and Rare Disease, Drug Watch/ June, 2017 The FDA approves Radicava; is it a breakthrough moment for ALS?
On Friday, May 5th, the FDA approved Mitsubishi Tanabe Pharma’s Radicava (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS), more... In DRG Blog, Niche and Rare Disease, Drug Watch/ May, 2017